Infinity Pharmaceuticals (Infinity Pharmaceuticals) Inventory-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Infinity Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Infinity Pharmaceuticals's Average Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil. Infinity Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $0.58 Mil. Infinity Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

Infinity Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2023 stayed the same from Mar. 2023 (0.00) to Mar. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Infinity Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Infinity Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Infinity Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Inventory-to-Revenue Chart

Infinity Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Inventory-to-Revenue

Get a 7-Day Free Trial

Infinity Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Infinity Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, Infinity Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Inventory-to-Revenue falls into.

Infinity Pharmaceuticals Inventory-to-Revenue Calculation

Infinity Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

	Inventory-to-Revenue (A: Dec. 2022 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )
=	( (0	+	0)	/	1 )	/	2.593
=	0					/	2.593
=	0.00

Infinity Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

	Inventory-to-Revenue (Q: Jun. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Mar. 2023 )	+	Total Inventories (Q: Jun. 2023 ))	/	count )	/	Revenue (Q: Jun. 2023 )
=	( (0	+	0)	/	1 )	/	0.583
=	0					/	0.583
=	0.00

Infinity Pharmaceuticals (OTCPK:INFIQ) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Infinity Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	0	/	0.352	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Infinity Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	0.352	/	0
	=

Infinity Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138

Website

https://www.infi.com

Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.

Executives

Adelene Q Perkins	director, officer: President & CEO	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso	officer: Chief Scientific Officer	1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria	officer: Chief Medical Officer	1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch	officer: EVP, CFO & CBO
Michael Kauffman	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti	director